tetano
Editor, Senior Moderator
J Med Virol
. 2020 Jun 3.
doi: 10.1002/jmv.26127. Online ahead of print.
Lopinavir/ritonavir and Interferon Combination Therapy May Help Shorten the Duration of Viral Shedding in Patients With COVID-19: A Retrospective Study in Two Designated Hospitals in Anhui, China
Yan Zuo[SUP] 1 [/SUP], Yunlei Liu[SUP] 2 [/SUP], Qi Zhong[SUP] 3 [/SUP], Ke Zhang[SUP] 1 [/SUP], Yuanhong Xu[SUP] 1 [/SUP], Zhongxin Wang[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Prolonged viral shedding may pose a threat to the control of coronavirus disease 2019 (COVID-19), and data on the duration of SARS-CoV-2 shedding are still limited, with the associated factors being unknown.
Methods: All adult patients with laboratory-confirmed COVID-19 were included in this retrospective cross-sectional study in two designated hospitals during 21 January 2020-16 March 2020 in Anhui, China. In all patients, data on the duration of SARS-CoV-2 RNA shedding were analyzed by reviewing all RNA detection results during hospitalization. Additionally, demographic, clinical, treatment, laboratory and outcome data were also collected from electronic medical records. Factors associated with prolonged viral shedding were analyzed with the Cox proportional hazards model.
Results: Among 181 patients, the mean age was 44.3?13.2 years, and 55.2% were male. The median duration of viral shedding from illness onset was 18.0 days (IQR 15.0-24.0). Prolonged viral shedding was associated with longer hospital stays (P<0.001) and higher medical costs (P<0.001). The severity of COVID-19 had nothing to do with prolonged shedding. Moreover, the median time from onset to antiviral treatment initiation was 5.0 days (IQR 3.0-7.0). Delayed antiviral treatment (HR 0.976 [95% CI, 0.962-0.990]) and lopinavir/ritonavir + IFN-α combination therapy as the initial antiviral treatment (HR 1.649 [95% CI, 1.162-2.339]) were independent factors associated with prolonged SARS-CoV-2 RNA shedding.
Conclusions: SARS-CoV-2 showed prolonged viral shedding, causing increased hospital stays and medical costs. Early initiation of lopinavir/ritonavir + IFN-α combination therapy may help shorten the duration of SARS-CoV-2 shedding. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; associated factors; outcomes; treatment; viral shedding.
. 2020 Jun 3.
doi: 10.1002/jmv.26127. Online ahead of print.
Lopinavir/ritonavir and Interferon Combination Therapy May Help Shorten the Duration of Viral Shedding in Patients With COVID-19: A Retrospective Study in Two Designated Hospitals in Anhui, China
Yan Zuo[SUP] 1 [/SUP], Yunlei Liu[SUP] 2 [/SUP], Qi Zhong[SUP] 3 [/SUP], Ke Zhang[SUP] 1 [/SUP], Yuanhong Xu[SUP] 1 [/SUP], Zhongxin Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 32492211
- DOI: 10.1002/jmv.26127
Abstract
Background: Prolonged viral shedding may pose a threat to the control of coronavirus disease 2019 (COVID-19), and data on the duration of SARS-CoV-2 shedding are still limited, with the associated factors being unknown.
Methods: All adult patients with laboratory-confirmed COVID-19 were included in this retrospective cross-sectional study in two designated hospitals during 21 January 2020-16 March 2020 in Anhui, China. In all patients, data on the duration of SARS-CoV-2 RNA shedding were analyzed by reviewing all RNA detection results during hospitalization. Additionally, demographic, clinical, treatment, laboratory and outcome data were also collected from electronic medical records. Factors associated with prolonged viral shedding were analyzed with the Cox proportional hazards model.
Results: Among 181 patients, the mean age was 44.3?13.2 years, and 55.2% were male. The median duration of viral shedding from illness onset was 18.0 days (IQR 15.0-24.0). Prolonged viral shedding was associated with longer hospital stays (P<0.001) and higher medical costs (P<0.001). The severity of COVID-19 had nothing to do with prolonged shedding. Moreover, the median time from onset to antiviral treatment initiation was 5.0 days (IQR 3.0-7.0). Delayed antiviral treatment (HR 0.976 [95% CI, 0.962-0.990]) and lopinavir/ritonavir + IFN-α combination therapy as the initial antiviral treatment (HR 1.649 [95% CI, 1.162-2.339]) were independent factors associated with prolonged SARS-CoV-2 RNA shedding.
Conclusions: SARS-CoV-2 showed prolonged viral shedding, causing increased hospital stays and medical costs. Early initiation of lopinavir/ritonavir + IFN-α combination therapy may help shorten the duration of SARS-CoV-2 shedding. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; associated factors; outcomes; treatment; viral shedding.